Literature DB >> 2198944

Bifunctional antibodies: concept, production and applications.

O Nolan1, R O'Kennedy.   

Abstract

Immunoglobulins, or antibodies, are monospecific, bivalent antigen-binding molecules. Bifunctional antibodies are bispecific, with each arm binding to a different antigen, and may be produced by biological or chemical methods. Biological production involves the fusion of two monoclonal antibody-producing hybridomas or of an immunised spleen cell and a hybridoma. The resulting hybrid hybridomas (quadromas or triomas) secrete a mixture of parenteral monoclonal antibodies and bifunctional antibody. In chemical production, the parental monoclonal antibodies can be 'chopped up and reconstituted' to produce the bifunctional antibody only. Bifunctional antibodies have a variety of potential uses. They were originally proposed as an aid to cancer chemotherapy where one of the arms of the antibody would bind to a tumour marker and the other to a drug, toxin, or cytotoxic cell. Functional agents can thus be target directly onto tumour cells, accumulating with higher density, yet with reduced side effects for the patient. Further applications have been proposed involving enzyme immobilization and novel immunoassay techniques. This review describes developments that have taken place in bifunctional antibody technology to date.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2198944     DOI: 10.1016/0167-4838(90)90139-7

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  8 in total

1.  Increased antigen binding strengths of hybrid antibodies produced by human hybrid hybridomas.

Authors:  H Tachibana; S Shirahata; H Kawahara; H Murakami
Journal:  Cytotechnology       Date:  1991-09       Impact factor: 2.058

2.  Capture of recombinant ricin A chain by a bispecific anti-RTA:anti-CEA monoclonal antibody pre-targeted to a human gastric carcinoma xenograft in nude mice.

Authors:  M V Pimm; R A Robins; R W Baldwin
Journal:  J Cancer Res Clin Oncol       Date:  1992       Impact factor: 4.553

3.  Dissociation of lethal toxicity and enzymic activity of notexin from Notechis scutatus scutatus (Australian-tiger-snake) venom by modification of tyrosine residues.

Authors:  C C Yang; L S Chang
Journal:  Biochem J       Date:  1991-12-15       Impact factor: 3.857

Review 4.  Antibody-directed therapy of multidrug-resistant tumor cells.

Authors:  T Efferth; M Volm
Journal:  Med Oncol Tumor Pharmacother       Date:  1992

5.  Preparation and properties of nido-carborane-specific monoclonal antibodies for potential use in boron neutron capture therapy for cancer.

Authors:  R H Pak; F J Primus; K J Rickard-Dickson; L L Ng; R R Kane; M F Hawthorne
Journal:  Proc Natl Acad Sci U S A       Date:  1995-07-18       Impact factor: 11.205

Review 6.  Development of bispecific antibodies in China: overview and prospects.

Authors:  Jing Zhang; Jizu Yi; Pengfei Zhou
Journal:  Antib Ther       Date:  2020-05-30

7.  Development of humanized bispecific antibodies reactive with cytotoxic lymphocytes and tumor cells overexpressing the HER2 protooncogene.

Authors:  M R Shalaby; H M Shepard; L Presta; M L Rodrigues; P C Beverley; M Feldmann; P Carter
Journal:  J Exp Med       Date:  1992-01-01       Impact factor: 14.307

8.  Discovery of hapten-specific scFv from a phage display library and applications for HER2-positive tumor imaging.

Authors:  Hye-Yeong Kim; Xiaolei Wang; Brendon Wahlberg; W Barry Edwards
Journal:  Bioconjug Chem       Date:  2014-06-18       Impact factor: 4.774

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.